Therefore, this study suggests that a potential molecular mechanism that induces central fatigue with an exogenous injection of TGF-β can be a useful animal model for a pharmaceutical investigation of CFS. Here, TGFB1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.